NICE accepts all three CDK4/6 inhibitors as comparators for each other, but none has ever faced exemestane plus everolimus head-to-head.

NICE's technology appraisals for the CDK4/6 inhibitor class in HR+/HER2- advanced breast cancer, TA836 for palbociclib plus fulvestrant, TA725 for abemaciclib plus fulvestrant, and TA687 for ribociclib plus fulvestrant, all treat the class as internally comparable. The committee concluded that abemaciclib plus fulvestrant and ribociclib plus fulvestrant are appropriate comparators for palbociclib plus fulvestrant, drawing on pivotal trials including MONARCH 2 (n=669, abemaciclib) and MONALEESA-3 (n=726, ribociclib). The three drugs share a mechanism but differ in dosing. Palbociclib and ribociclib are once-daily for 21 of a 28-day cycle, while abemaciclib is twice-daily continuously, a PICO-relevant distinction that shapes tolerability comparisons.

The comparator framework has a real gap outside the class itself. No trial directly compares ribociclib plus fulvestrant, or either of its class-mates, against exemestane plus everolimus, the endocrine-based regimen that was standard of care before CDK4/6 inhibitors arrived. That absence matters for any new entrant's HTA submission. NICE's within-class comparator acceptance does not extend automatically to a comparator outside the class, and a submission that assumes it does risks exactly the kind of committee pushback that HEOR teams should price in before the dossier is finalised. The gap register scores this specific comparator absence by likelihood of being raised and impact if it is.

Within-class comparators are accepted; the pre-CDK4/6 standard of care was never tested against them.

Five questions this report answers:

Q1 - Does NICE's within-class CDK4/6 comparator acceptance extend to exemestane plus everolimus?

Q2 - How should a new HTA submission's PICO framework handle the CDK4/6 class's dosing differences?

Q3 - What does a likelihood-times-impact HEOR gap register score that a simple evidence-gap list doesn't?

Q4 - How large were the MONARCH 2 and MONALEESA-3 trials underpinning NICE's comparator acceptance?

Q5 - Why does dosing schedule matter for tolerability comparisons across the three CDK4/6 inhibitors?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HTAStrategy #NICE #CDK46Inhibitor #BreastCancer #HEOR #UK

Live report page:  https://axlrx.ai/breast-cancer-hr-positive-her2-negative/uk/hta-strategy-model/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/